Core Viewpoint - The article discusses the financial and governance crisis faced by Clear Medical (01406.HK), a Hong Kong-listed ophthalmology service provider, following multiple trading suspensions and allegations of systematic fraud during its IPO process [1][2][9]. Group 1: Company Background and IPO - Clear Medical was considered a "star IPO" in 2022, raising HKD 218 million at an issue price of HKD 1.60 per share [2]. - The company claimed that its founders received a fixed salary of HKD 200,000 per month, which contributed significantly to its reported profits during the fiscal years 2019-2021 [2]. - However, it was revealed that the founders actually received performance-based variable compensation, with one founder's actual salary reaching HKD 12.61 million in the 2019 fiscal year, contradicting the IPO disclosures [2][3]. Group 2: Financial Performance Post-IPO - Following the termination of fixed salary contracts by the founders, Clear Medical's net profit plummeted to a loss of HKD 3.19 million in the 2023 fiscal year, down from a profit of HKD 13.49 million in 2022 [3]. - The company distributed HKD 148 million in dividends from 2019 to 2021, exceeding its total profits during that period by 40% [3]. Group 3: Allegations and Key Individuals - An anonymous email alleged that a key figure, Mok Tsan San, acted as an intermediary for "illegal IPO funds" and attempted to manipulate the new management team [4][5]. - Mok has a controversial history, having been involved in companies that faced significant stock price declines and eventual delistings [5]. - The article highlights ongoing concerns regarding the old management team, particularly regarding their influence and potential attempts to undermine the new management [7][8]. Group 4: Regulatory Actions and Market Implications - The Hong Kong Securities and Futures Commission is expected to investigate the allegations, which raises broader concerns about the integrity of the IPO process and corporate governance in the Hong Kong market [9]. - The article emphasizes the need for a shift towards transparent and responsible management to restore trust in the Hong Kong capital market [9].
清晰医疗(01406.HK)的停牌迷局